Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
نویسندگان
چکیده
BACKGROUND Antibodies against HLA antigens cause refractory allograft rejection with vasculopathy in some, but not all, patients. METHODS We studied 33 kidney-transplant recipients who had refractory vascular rejection. Thirteen had donor-specific anti-HLA antibodies, whereas 20 did not. Malignant hypertension was present in 16 of the patients without anti-HLA antibodies, 4 of whom had seizures. The remaining 17 patients had no malignant hypertension. We hypothesized that activating antibodies targeting the angiotensin II type 1 (AT1) receptor might be involved. RESULTS Activating IgG antibodies targeting the AT1 receptor were detected in serum from all 16 patients with malignant hypertension and without anti-HLA antibodies, but in no other patients. These receptor-activating antibodies are subclass IgG1 and IgG3 antibodies that bind to two different epitopes on the second extracellular loop of the AT1 receptor. Tissue factor expression was increased in renal-biopsy specimens from patients with these antibodies. In vitro stimulation of vascular cells with an AT1-receptor-activating antibody induced phosphorylation of ERK 1/2 kinase and increased the DNA binding activity of the transcription factors activator protein 1 (AP-1) and nuclear factor-kappaB. The AT1 antagonist losartan blocked agonistic AT1-receptor antibody-mediated effects, and passive antibody transfer induced vasculopathy and hypertension in a rat kidney-transplantation model. CONCLUSIONS A non-HLA, AT1-receptor-mediated pathway may contribute to refractory vascular rejection, and affected patients might benefit from removal of AT1-receptor antibodies or from pharmacologic blockade of AT1 receptors.
منابع مشابه
Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection
BACKGROUND Angiotensin II type 1 receptor (AT1R) is responsible for cardiovascular effects mediated by angiotensin II. This study aimed to investigate the impact of antibodies directed against AT1R (anti-AT1R) in renal allograft rejection. METHODS We evaluated 53 patients who had biopsy-proven rejection including antibody-mediated rejection (AMR) (N=22), T-cell-mediated rejection (TCMR) (N=29...
متن کاملAngiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection
Duska Dragun, M.D., Dominik N. Müller, Ph.D., Jan Hinrich Bräsen, M.D., Lutz Fritsche, M.D., Melina Nieminen-Kelhä, B.S., Ralf Dechend, M.D., Ulrich Kintscher, M.D., Birgit Rudolph, M.D., Johan Hoebeke, Ph.D., Diana Eckert, M.D., Istvan Mazak, M.D., Ralph Plehm, Ph.D., Constanze Schönemann, Ph.D., Thomas Unger, M.D., Klemens Budde, M.D., Hans-Hellmut Neumayer, M.D., Friedrich C. Luft, M.D., and...
متن کاملThe Presence of Anti-Angiotensin II Type-1 Receptor Antibodies Adversely Affect Kidney Graft Outcomes
The aim of this study was to determine whether anti-angiotensin type 1 receptor antibodies (AT1R-Abs) are related to acute rejection (AR) and kidney graft failure in renal transplantation. We searched electronic databases including MEDLINE, EMBASE, and the ISI Web of Science databases for all studies on the association between anti-angiotensin type 1 receptor antibodies and kidney allograft out...
متن کاملNon-HLA Antibody Induced Agonism on the Angiotensin II Type 1 Receptor in Renal Allograft Vascular Injury
The rising incidence of steroid-refractory rejections is a challenging problem in renal allotransplantation. Etiological studies implicate either an overwhelming T-cell response or, more frequently, involvement of alloantibodies. Alloantibodies induce a spectrum of histologic tubulointerstitial and vascular changes paralleled with immunohistochemical positivity for C4d along peritubular capilla...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The New England journal of medicine
دوره 352 19 شماره
صفحات -
تاریخ انتشار 2005